Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
Fondazione Telethon ETS
BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
1 trial -
Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043
Lacuna Pharma Pty Ltd
Metastatic solid tumors, Advanced solid tumors
1 trial -
LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
1 trial -
MDNA11
Medicenna Therapeutics
Advanced Solid Tumor
1 trial -
MK-3120
Merck Sharp and Dohme
Advanced/metastatic solid tumor disease
1 trial -
MKC-1
CASI Pharmaceuticals
Advanced Cancer
2 trials -
MRTX1719
Bristol-Myers Squibb Australia Pty Ltd
Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
MaaT033 capsule
Regeneron UK Limited
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Medtronic PrimeADVANCED Neurostimulator
Rhythm Pharmaceuticals Netherlands B.V.
Heart Failure
1 trial -
Monalizumab
MedImmune
Advanced Solid Tumors
1 trial -
NIVOLUMAB, BT5528
BICYCLE THERAPEUTICS
Advanced Malignancies Associated with EphA2 Expression
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Breast Cancer
1 trial -
Nivolumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Biliary Tract Cancer(BTC)
1 trial -
Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB
Bristol-Myers Squibb Australia Pty Ltd
Advanced Solid Tumors
1 trial -
OLAPARIB, BEVACIZUMAB
The George Institute
Advanced FIGO Stage IIIβIV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer
1 trial -
ONC201
Jazz Pharmaceuticals Ireland Limited
Advanced Glioblastoma
1 trial -
ONC206
Jazz Pharmaceuticals Ireland Limited
Advanced Pheochromocytoma and Paraganglioma
1 trial -
ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL
Lacuna Pharma Pty Ltd
PD-L1 positive advanced colorectal cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., BDC-1001, OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.
Bolt Biotherapeutics
Advanced HER2-Expressing Solid Tumors.
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL , Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL , SIMVASTATIN, CAPECITABINE
Fondazione Telethon ETS
advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Ipilimumab
Bristol-Myers Squibb Australia Pty Ltd
Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB
The George Institute
Locally-advanced stage II-III rectal cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous
The George Institute
Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.
Bristol-Myers Squibb Australia Pty Ltd
Advanced/metastatic hepatocellular carcinoma (HCC)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources